Mehra Raj's Form 4 filing
Seelos Therapeutics, Inc. (SEEL) · filed Dec 1, 2023
- Accession no.
- 0001104659-23-122840
- Filed
- Dec 1, 2023
- Trade date
- Dec 1, 2023
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $100.0K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mehra RajCIK 0001757892 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2023 | Common Stock | PPurchaseAcquired | +75,757 | $1.32F1 | +$99,999.24 | 185,142 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2023 | Common Stock | PPurchaseAcquired | +75,757 | –F1 | – | 75,757 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of common stock was purchased together with an accompanying warrant to purchase one share of common stock in an underwritten public offering at a combined offering price of $1.32 per share of common stock and accompanying warrant.
Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.
Remarks
President, Chief Executive Officer and Chairman of the Board of Directors